|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
A meeting yesterday between FDA senior staff and rare disease nonprofit leaders is giving a sense of where acting Commissioner Kyle Diamantas is directing the agency. He said that he'd prevent interference in decisions staff are making around drug candidates, Zach Brennan reports. |
|
|
|
Lydia Ramsey Pflanzer |
Deputy Editor, Endpoints News
|
|
|
|
 |
|
Acting FDA Commissioner Kyle Diamantas (Francis Chung/Politico via AP Images) |
|
|
|
by Zachary Brennan
|
Executives from 15 rare disease-focused nonprofits met on Wednesday with acting FDA Commissioner Kyle Diamantas and senior staff. In the meeting, Diamantas made it clear... | |
|
|
|
|
|
|
by Nicole DeFeudis
|
The Supreme Court unanimously sided with Hikma Pharmaceuticals and its “skinny label” version of a prescription-strength fish oil pill in a case that was closely... | |
|
|
|
|
|
|
by Anna Brown
|
Novo Nordisk’s troubled factory in Indiana that it got from Catalent continues to face contamination issues, with a re-inspection in April finding mammalian hair in... | |
|
|
|
 |
|
From left to right: Dimension Capital co-founders Nan Li, Zavain Dar and Adam Goulburn |
|
|
|
by Kyle LaHucik
|
Dimension Capital, an investment firm focused on the convergence of machine learning and life sciences, is raising its third batch of capital and seeking up... | |
|
|
|
|
|
|
by Ayisha Sharma
|
Backlash is brewing against a sweeping overhaul of Germany’s health insurance system as Eli Lilly and Boehringer Ingelheim slash investment in the country. The drugmakers'... | |
|
|
|
|
|
|
by Reynald Castaneda
|
ADC Therapeutics’ bid to secure full approval for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma has been complicated by death rates in its... | |
|
|
|
|
|
